JOIN OUR TEAM
We are developing new pan-cancer therapeutics leveraging the ELANE pathway to selectively kill cancer cells. Our experienced team has carved a path over decades of academic and industry roles. We are motivated to confront unmet medical needs in the world with novel and compelling science.
Open Positions
LATEST NEWS
Keep up to date with all the latest news from Onchilles Pharma
Onchilles Pharma to Present OP-NEU-101 Trial in Progress at ESMO Congress 2026
N17350 is designed to leverage the ELANE pathway, a cancer-selective mechanism that induces immunogenic cancer cell death while sparing healthy tissue, including immune cells. In preclinical studies, N17350 demonstrated broad tumor-killing activity, immune cell preservation, and activation of anti-tumor immunity across multiple solid tumor models.
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors
N17350 is designed to leverage the ELANE pathway, a cancer-selective mechanism that induces immunogenic cancer cell death while sparing healthy tissue, including immune cells. In preclinical studies, N17350 demonstrated broad tumor-killing activity, immune cell preservation, and activation of anti-tumor immunity across multiple solid tumor models.
Subscribe To Our Newsletter
Keep up to date with all the latest news from Onchilles Pharma